NCT00384085 arm group 93b596e9da5ed1f39d505bbb4b5746a1 [clinicaltrials_resource:NCT00384085/arm-group/93b596e9da5ed1f39d505bbb4b5746a1]
arm group [clinicaltrials_vocabulary:arm-group]
NCT00384085 arm group 93b596e9da5ed1f39d505bbb4b5746a1 [clinicaltrials_resource:NCT00384085/arm-group/93b596e9da5ed1f39d505bbb4b5746a1]
Bio2RDF identifier
NCT00384085/arm-group/93b596e9da5ed1f39d505bbb4b5746a1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... b596e9da5ed1f39d505bbb4b5746a1
description [clinicaltrials_vocabulary:description]
Insulin glargine (Lantus) plus ...... (Apidra) added to oral agents.
identifier
clinicaltrials_resource:NCT00384085/arm-group/93b596e9da5ed1f39d505bbb4b5746a1
title
NCT00384085 arm group 93b596e9da5ed1f39d505bbb4b5746a1
@en
type
label
NCT00384085 arm group 93b596e9 ...... 596e9da5ed1f39d505bbb4b5746a1]
@en